Aimmune Therapeutics, Inc.
(NASDAQ : AIMT)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.51%195.081.3%$540.00m
GILDGilead Sciences, Inc.
-0.59%65.490.9%$358.26m
ALXNAlexion Pharmaceuticals, Inc.
-0.39%108.122.0%$334.53m
ILMNIllumina, Inc.
-0.08%300.663.5%$306.31m
BIIBBiogen Inc.
-0.46%235.041.3%$295.66m
CELGCelgene Corporation
0.38%98.761.3%$286.59m
SRPTSarepta Therapeutics, Inc.
-2.55%84.8014.6%$180.93m
VRTXVertex Pharmaceuticals Incorporated
-1.04%175.701.9%$172.86m
AAgilent Technologies, Inc.
-0.44%76.811.6%$172.64m
REGNRegeneron Pharmaceuticals, Inc.
-0.07%285.692.6%$171.07m
EXASExact Sciences Corporation
0.97%105.4224.1%$133.13m
ACADACADIA Pharmaceuticals Inc.
-2.23%43.0313.9%$114.83m
INCYIncyte Corporation
-0.45%77.992.5%$84.99m
BMRNBioMarin Pharmaceutical Inc.
-1.54%73.074.3%$69.26m
IONSIonis Pharmaceuticals, Inc.
-0.63%64.728.2%$63.12m

Company Profile

Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.